JP2022544803A - 筋肉消耗及び他の状態の治療及び予防に好適な化合物 - Google Patents

筋肉消耗及び他の状態の治療及び予防に好適な化合物 Download PDF

Info

Publication number
JP2022544803A
JP2022544803A JP2022510087A JP2022510087A JP2022544803A JP 2022544803 A JP2022544803 A JP 2022544803A JP 2022510087 A JP2022510087 A JP 2022510087A JP 2022510087 A JP2022510087 A JP 2022510087A JP 2022544803 A JP2022544803 A JP 2022544803A
Authority
JP
Japan
Prior art keywords
myomed
group
compound
methyl
muscle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022510087A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022544803A5 (https=
JPWO2021032643A5 (https=
Inventor
アダムス，フォルカー
ラベイト，ジークフリート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2022544803A publication Critical patent/JP2022544803A/ja
Publication of JP2022544803A5 publication Critical patent/JP2022544803A5/ja
Publication of JPWO2021032643A5 publication Critical patent/JPWO2021032643A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2022510087A 2019-08-16 2020-08-14 筋肉消耗及び他の状態の治療及び予防に好適な化合物 Pending JP2022544803A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19192107.1 2019-08-16
EP19192107 2019-08-16
PCT/EP2020/072911 WO2021032643A1 (en) 2019-08-16 2020-08-14 Compounds suitable for the treatment and prophylaxis of muscle wasting and other conditions

Publications (3)

Publication Number Publication Date
JP2022544803A true JP2022544803A (ja) 2022-10-21
JP2022544803A5 JP2022544803A5 (https=) 2023-08-17
JPWO2021032643A5 JPWO2021032643A5 (https=) 2023-08-17

Family

ID=67659191

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022510087A Pending JP2022544803A (ja) 2019-08-16 2020-08-14 筋肉消耗及び他の状態の治療及び予防に好適な化合物

Country Status (13)

Country Link
US (1) US12331042B2 (https=)
EP (1) EP4013497B1 (https=)
JP (1) JP2022544803A (https=)
KR (1) KR20220047807A (https=)
CN (1) CN114302881B (https=)
AU (1) AU2020334194A1 (https=)
BR (1) BR112022002769A2 (https=)
CA (1) CA3144700A1 (https=)
CL (1) CL2022000320A1 (https=)
IL (1) IL290540A (https=)
MX (1) MX2022002022A (https=)
WO (1) WO2021032643A1 (https=)
ZA (1) ZA202202863B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102823820B1 (ko) * 2022-09-01 2025-06-23 단국대학교 천안캠퍼스 산학협력단 퓨로크로멘온계 화합물을 유효성분으로 포함하는 근감소증 예방 또는 치료용 약학 조성물
AU2023348158A1 (en) * 2022-09-30 2025-02-27 Société des Produits Nestlé S.A. Composition and method for treating muscle decline associated with renal disease or dysfunction

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012154213A1 (en) * 2011-04-07 2012-11-15 Cornell University Cofluorons and methods of making and using them
WO2015010107A1 (en) * 2013-07-18 2015-01-22 Baylor College Of Medicine Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia
US20150094307A1 (en) * 2013-10-01 2015-04-02 Ann Marie Schmidt Amino, amido and heterocyclic compounds as modulators of rage activity and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2624524C (en) * 2005-09-29 2014-07-08 Elan Pharmaceuticals, Inc. Carbamate compounds which inhibit leukocyte adhesion mediated by vla-4
EP2072528A1 (en) 2007-12-19 2009-06-24 Labeit, Mr. Siegfried A host cell deficient for MuRF1 and MuRF2
AU2012268036B2 (en) * 2011-06-06 2017-04-06 THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF STATE OF THE DEPARTMENT OF VETERANS AFFAIRS Methods of inhibiting muscle atrophy
CN112274183A (zh) * 2020-11-02 2021-01-29 李云莹 一种神经内科用脑部超声波治疗装置

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012154213A1 (en) * 2011-04-07 2012-11-15 Cornell University Cofluorons and methods of making and using them
WO2015010107A1 (en) * 2013-07-18 2015-01-22 Baylor College Of Medicine Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia
US20150094307A1 (en) * 2013-10-01 2015-04-02 Ann Marie Schmidt Amino, amido and heterocyclic compounds as modulators of rage activity and uses thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
REGISTRY (STN) [ONLINE], JPN7024003301, ISSN: 0005386364 *
REGISTRY (STN) [ONLINE], JPN7024003302, ISSN: 0005386363 *
REGISTRY (STN) [ONLINE], JPN7024003303, ISSN: 0005386365 *
REGISTRY (STN) [ONLINE], JPN7024003304, ISSN: 0005386366 *
REGISTRY (STN) [ONLINE], JPN7024003305, ISSN: 0005386367 *
REGISTRY (STN) [ONLINE], JPN7024003306, ISSN: 0005386368 *

Also Published As

Publication number Publication date
AU2020334194A1 (en) 2022-02-24
US12331042B2 (en) 2025-06-17
WO2021032643A1 (en) 2021-02-25
EP4013497B1 (en) 2023-10-04
EP4013497C0 (en) 2023-10-04
EP4013497A1 (en) 2022-06-22
US20220324852A1 (en) 2022-10-13
CN114302881B (zh) 2025-03-25
CN114302881A (zh) 2022-04-08
KR20220047807A (ko) 2022-04-19
CL2022000320A1 (es) 2023-02-03
ZA202202863B (en) 2023-10-25
CA3144700A1 (en) 2021-02-25
MX2022002022A (es) 2022-05-11
BR112022002769A2 (pt) 2022-05-10
IL290540A (en) 2022-04-01

Similar Documents

Publication Publication Date Title
JP5921679B2 (ja) 血漿カリクレインの阻害薬としてのベンジルアミン誘導体
JP5423675B2 (ja) アゾール化合物
BR112016009488B1 (pt) piperidil-etil-pirimidina substituída, seus usos, e composição farmacêutica
JP2010519334A (ja) イミダゾ［１，２−ａ］ピリジンおよびそれらの薬剤としての使用
AU2015238789B2 (en) Indoline compounds as granzyme b inhibitors
US10329324B2 (en) Indoline compounds as granzyme B inhibitors
CN115701991A (zh) 吡唑基丙酰胺化合物及其用于治疗前列腺癌的用途
CN107074839A (zh) 用于治疗代谢和体重相关的病症的组合物和方法
TW201038275A (en) Synthesis of pulmodil and pulmodil-1, two chlorophenylpiperazine salt derivatives, and rhokinase-dependent inhibition activity on pulmonary artery endothelium dysfunction, medial wall thickness and vascular obstruction thereof
WO2012075678A1 (zh) 取代噻唑基吡唑并吡啶类化合物及其医药用途
AU2015296675B2 (en) Cyclic urea compounds as Granzyme B inhibitors
US12006321B2 (en) Substituted pyrazolo[1,5-a]pyrimidines as apelin receptor agonists
US12331042B2 (en) Compounds suitable for the treatment and prophylaxis of muscle wasting and other conditions
CN102325768B (zh) 治疗疼痛和其他疾病的化合物和方法
ES2267148T3 (es) Productos farmaceuticos para curar y prevenir las efermedades resultantes del daño de las celulas endoteliales vascular.
US20110144197A1 (en) Alcanoic acid amides substituted by saturated o-heterocycles
US7176199B2 (en) Aryl-substituted alicyclic compound and medical composition comprising the same
US8530453B2 (en) Compounds and methods for the treatment of pain and other diseases
RU2542980C2 (ru) Замещенные производные 3-бензофуранил-индол-2-он-3-ацетамидопиперазинов, их получение и их применение в терапии
CN109758459B (zh) 取代的吡啶的新用途
CN108290868B (zh) 1,4-二-(4-甲硫基苯基)-3-邻苯二甲酰氮杂环丁烷-2-酮及其衍生物
JPWO2015046404A1 (ja) 肺高血圧症の治療剤又は予防剤
WO2023028117A1 (en) Methods of treating cdgsh iron sulfur domain 2 insufficiency-associated disorders
CN102690238A (zh) 巴比妥酸衍生物作为rsk2抑制剂的合成与应用
HK40125827A (zh) 噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230808

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230808

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240711

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241105

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250212